Skip to main content

Morgan Godvin Found Her People in a Newsroom. Washington Turned Off the Money, and the Newsroom Died Too.

Filter's August 11 closure isn't a media story. It's what funding whiplash looks like when it finally lands on the smallest, most trusted link in the harm reduction chain.

ByThe Rize NewsroomAugust 25, 202610 min readOpioids

Morgan Godvin found Filter about a year after she got out of prison. She has told the story herself, in the plain, unromantic way people who’ve lived it tend to tell it: she was rebuilding a life with almost nothing, and a small nonprofit newsroom covering drugs, policy, and the people living both, wrote back to her. “The stories I wrote and read connected me with people all over the country,” she said in the statement Filter published on August 11, the day the outlet announced it was closing. She’s a board member now. She was one of the last people asked to say something before the lights went off.

Filter didn’t get killed by one bad headline or one furious advertiser. It got killed the same way a syringe program or a naloxone training line gets killed: a funding landscape built to yank money out from under people with almost no warning, over and over, until the org with the thinnest margin can’t absorb the next hit.

That’s the sentence to sit with, because it’s the one this story is actually about. Filter is a media outlet, not a treatment provider, and its closure will not, by itself, cost anyone their life the way a defunded syringe service program can. But editor-in-chief Will Godfrey’s statement named the mechanism plainly: Filter was “unable to survive an increasingly difficult funding landscape, like too many other harm reduction and independent media organizations.” Read that sentence again. He didn’t say Filter ran out of ideas, or readers, or relevance. He said the landscape did it. And the landscape he’s talking about is the same one that, this year, has been switching addiction and harm reduction funding on and off like a light with a bad wire.

If you’ve worked harm reduction — as staff, as a volunteer, as someone who’s picked up test strips or a naloxone kit from a table you weren’t sure would still be there next month — you already know what that landscape feels like from the inside. You don’t need it explained to you. What you might not have had is the paper trail. Filter’s closure is a good place to start building one, because it’s small enough to see clearly and connected enough to explain the rest.

The reversal that didn’t undo the damage

Here’s the part of the story that a lot of coverage undersold: the federal government terminated, and then rapidly restored, a huge share of behavioral health funding this year — and the restoration didn’t put anyone back where they started.

“Discretionary” is a word worth pinning down before the numbers land: it means a grant HHS can end on its own signature, without a vote of Congress — which is exactly why it can also be ended overnight, by letter, with no more than a one-line justification. On January 13 and 14, 2026, the Substance Abuse and Mental Health Services Administration sent termination notices covering exactly that kind of money: somewhere between 2,000 and 2,900 individual discretionary grants, roughly $1.9 to $2 billion in total — about a quarter of SAMHSA’s entire discretionary budget. The letters themselves cited “adjusting its discretionary award portfolio” or “non-alignment with SAMHSA priorities” — no program-by-program reasoning, no list of what specifically had failed. Addiction treatment, mental health services, suicide prevention lines, homelessness assistance, workforce training, recovery housing, and harm reduction programs were all inside that $2 billion, undifferentiated.

Then, about 24 hours later, HHS reversed course and restored the money. If you only read the headline, that sounds like a story with a happy ending. It isn’t one. A grantee that just got a termination letter doesn’t un-furlough the staff member they laid off that morning. A syringe program that told its regulars the mobile unit might not run next week doesn’t get those regulars back just because a press release says the money’s flowing again. Whiplash has a cost even when the car doesn’t crash. Ask anyone who runs a nonprofit on a monthly cash-flow spreadsheet what a 24-hour funding gap does to their ability to plan April, June, the fiscal year. Filter ran on exactly that kind of margin. So does most of the harm reduction sector.

A grantee that just got a termination letter doesn’t un-furlough the staff member they laid off that morning.

The January reversal sat inside a longer pattern. In July 2025, the White House signed an executive order titled “Ending Crime and Disorder on America’s Streets,” directing SAMHSA’s discretionary grants toward programs the order calls “evidence-based” and explicitly away from what it calls “harm reduction” or “safe consumption” efforts. It’s worth naming the gate here plainly, because overstating this order is its own kind of harm: the order’s text targets safe consumption sites and similar programs, and SAMHSA has since clarified that naloxone distribution, drug-checking supplies like fentanyl test strips, and sharps disposal remain grant-eligible. The order didn’t zero out harm reduction on paper. What it did was signal, loudly, to every grant officer and every state health department writing next year’s budget, which way the wind inside the federal government was blowing — and wind like that shows up in a hundred smaller, quieter funding decisions that never make a headline of their own.

That’s the climate Filter was trying to raise money in — the same policy and funding climate we track here every week, because it decides which opioid treatment and harm reduction programs are still standing six months from now.

What gets cut is never the mission statement

Nobody’s grant termination letter ever says “we are cutting the thing that keeps people alive.” What gets cut are the specific, unglamorous line items underneath the mission statement — the mobile testing van’s gas budget, the peer-support stipend, the one salaried journalist covering a beat too small for a legacy newsroom to bother with. Filter covered exactly that beat: drug policy, harm reduction science, and the lived reality of people who use drugs, written substantially by people who use or have used drugs themselves. Deputy Editor Kastalia Medrano. Senior Editor Helen Redmond. Tobacco Harm Reduction Fellow Kiran Sidhu. Former staff Sessi Kuwabara Blanchard, Alex Norcia, Alexander Lekhtman. Hundreds of contributing writers over the outlet’s run, named in Godfrey’s closing statement with the specificity of someone who knows exactly who did the actual work.

Board member Diane Goldstein, a former police lieutenant who’s spent decades in drug policy reform, put it in terms that don’t need translating: “I helped build Filter because I believe people who use drugs deserve to be seen with dignity,” she said in the same statement. “Watching it close feels like losing a piece of my own family.” That’s not a metaphor for a funding gap. It’s a description of what a funding gap actually removes — not a budget line, a family.

This is where the pattern connects to the bigger, colder numbers. The CDC’s Overdose Data to Action program — the mechanism that funds states and localities to track overdose trends and route resources to where they’re spiking — has also been targeted for cuts and freezes this year, part of a broader federal pullback that outside trackers estimate in the billions across CDC’s overall grant portfolio. Nobody is proposing to cancel “overdose surveillance” as a stated goal. What gets frozen, instead, is the specific grant that pays for the specific epidemiologist who notices, three weeks early, that a new fentanyl analog just showed up in the supply in one county — the kind of signal that, when it’s funded, becomes a public health alert, and when it isn’t, becomes a spike in the death count that nobody saw coming until the data caught up months later.

The history that makes this feel familiar

We have watched a government decide that a cheap thing which keeps people alive sends the wrong message before. In 1988, at the height of the AIDS epidemic, Congress banned the use of federal funds for syringe exchange programs — the single intervention with the strongest evidence for slowing HIV transmission among people who inject drugs. The ban held, almost unbroken, for 21 years, through both parties, while a generation of people who injected drugs died of an entirely preventable bloodborne infection because the tool that could have stopped it wasn’t allowed to touch federal money. Congress didn’t lift it until December 2009. The argument for the ban was never “we don’t care if people die.” It was always some version of what the 2025 executive order says now: that funding the thing that reduces harm looks like endorsing the behavior that causes it. That argument has never once been supported by the epidemiology. It has, every time it’s won, cost lives that a cheaper, better-funded harm reduction infrastructure would have saved.

It has, every time it’s won, cost lives that a cheaper, better-funded harm reduction infrastructure would have saved.

That’s not a history lesson tacked on for color. It’s the pattern this week’s news is repeating, with a media outlet standing in this time for a syringe van.

It’s also repeating at the exact moment the strategy was working. CDC’s provisional count for the year ending January 2026 put overdose deaths at 69,147 — down 13.2% from the year before, part of a decline of nearly 21% since the 2025 peak. That drop is not an accident or a statistical fluke; public health researchers attribute it to the exact combination of tools now sitting inside the funding fights — naloxone access, low-barrier buprenorphine, and harm reduction outreach among them. Hanna Sharif-Kazemi, federal policy manager at the Drug Policy Alliance, warned that pulling federal money out from under that infrastructure forces states to “reduce essential services” across healthcare, education, and public safety alike — a slower, quieter version of the same math a newsroom runs when its grant disappears.

What’s still yours, and where the money is actually going in Arizona

Here’s what didn’t get cut, and it matters that you hear it plainly: naloxone remains federally fundable, fentanyl test strips remain federally fundable, 988 remains funded and staffed. Whatever else this year’s whiplash has done, the specific tools that stop an overdose in the moment it’s happening are still there, still legal to fund, still legal to hand out. If you’re carrying naloxone or you know where to get it, that hasn’t changed. That’s yours tonight, regardless of what happens in Washington next quarter.

And funding is not moving in only one direction. Arizona is a useful counterexample to hold next to Filter’s closure, not because it cancels out the national picture, but because it shows the money can flow the other way when a state chooses to route it there. Arizona is due up to $1.215 billion in opioid settlement funds over 18 years under the One Arizona Agreement — legal-settlement money that sits entirely outside the federal discretionary-grant fights above, immune to a SAMHSA termination letter. This July, AHCCCS released a Request for Grant Applications for an Opioid Antagonist Distribution Initiative, aimed specifically at expanding naloxone access and provider training in rural Arizona, where the nearest overdose reversal kit can be a genuine drive away. That’s a state deciding, deliberately, to put settlement dollars into exactly the kind of infrastructure the federal picture keeps threatening — proof that the outcome here isn’t fixed, it’s a choice being made differently in different places, right now, with money that already exists.

If you work in this field — provider, case manager, or peer specialist — the concrete move this week isn’t philosophical. It’s audit your program’s federal-discretionary exposure against your state-settlement exposure, and if you don’t know that ratio off the top of your head, that’s the gap to close before the next termination letter, not after it.

Godvin closed her statement about Filter the way people who’ve actually lived the thing they’re covering tend to close things: without a bow on it. She didn’t say the mission would live on somewhere else, or that something would rise to fill the gap. She said what the newsroom gave her was the feeling of not being alone in it — connected to people all over the country living some version of the same thing. That’s the thing a defunded program takes that never shows up in a budget memo: not a service, a signal to the people it reached that somebody was still there. Filter’s archive stays online. The people it reached are still out there too, and so is the argument it spent years making — that the version of harm reduction that keeps people alive is worth funding on purpose, not by accident, and not for 24 hours at a time.

She didn’t say the mission would live on somewhere else, or that something would rise to fill the gap.

Filed Under

policyharm-reductionHarm ReductionSAMHSANaloxoneOpioid Settlement

Keep up with the reporting.

One email each morning with the stories that put days like this in context.

A daily, no-spam briefing. Unsubscribe anytime.

Continue reading

More from this section